Education
About Us
Working with TipRanks
Follow Us
Rapt Therapeutics Inc (DE:0RA)
:0RA
0RA Stock Chart & Stats
Day’s Range― - ―
52-Week Range€0.95 - €8.65
Previous CloseN/A
Volume0.00
Average Volume (3M)63.00
Market Cap
€127.68M
Enterprise Value-€152.80M
Total Cash (Recent Filing)-$47.52M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-0.40
Next Earnings
May 08, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding132,006,820
10 Day Avg. Volume190
30 Day Avg. Volume63
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.10
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.13
Forecast
1Y Price Target
€5.47Price Target Upside447.47% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
RAPT Therapeutics News
PremiumCompany Announcements
RAPT Therapeutics Announces Board Restructuring in 2025
PremiumCompany Announcements
RAPT Therapeutics Focuses on RPT904 Development in 2025
PremiumCompany Announcements
RAPT Therapeutics Plans Phase 2b Trials for RPT904---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe initiation of the Ph2b trial for RPT904 in food allergy is on track, indicating strong progress in the company's development pipeline.
Financial StabilityThe company has a solid cash position of approximately $231 million, providing financial stability to support upcoming clinical milestones.
Licensing And Market ExpansionRAPT gaining worldwide development and commercialization rights to RPT904, excluding mainland China, Hong Kong, and Macau, represents a constructive step forward for their broader immunology pipeline.
Bears Say
Financial PerformanceRAPT recorded a full-year 2024 net loss of $3.19 per share, which was higher than the estimated net loss.
Market CompetitionPending competition from omalizumab biosimilars is expected to be an area of focus for investors.
Pricing PressureRAPT anticipates pricing erosion of 40% due to Xolair patent expiration and entry of biosimilar products, despite a potential price premium for RPT904.
---
Options Prices
Currently, No data available
---
Ownership Overview
6.10% Insiders
23.74%
Mutual Funds
0.13% Other Institutional Investors
63.59% Public Companies and
Individual Investors
0RA FAQ
What was Rapt Therapeutics Inc’s price range in the past 12 months?
Rapt Therapeutics Inc lowest stock price was €0.94 and its highest was €8.65 in the past 12 months.
What is Rapt Therapeutics Inc’s market cap?
Rapt Therapeutics Inc’s market cap is €127.68M.
When is Rapt Therapeutics Inc’s upcoming earnings report date?
Rapt Therapeutics Inc’s upcoming earnings report date is May 08, 2025 which is in 32 days.
How were Rapt Therapeutics Inc’s earnings last quarter?
Rapt Therapeutics Inc released its earnings results on Mar 06, 2025. The company reported -€1.054 earnings per share for the quarter, missing the consensus estimate of -€0.295 by -€0.759.
Is Rapt Therapeutics Inc overvalued?
According to Wall Street analysts Rapt Therapeutics Inc’s price is currently Undervalued.
Does Rapt Therapeutics Inc pay dividends?
Rapt Therapeutics Inc does not currently pay dividends.
What is Rapt Therapeutics Inc’s EPS estimate?
Rapt Therapeutics Inc’s EPS estimate is -0.12.
How many shares outstanding does Rapt Therapeutics Inc have?
Rapt Therapeutics Inc has 132,006,820 shares outstanding.
What happened to Rapt Therapeutics Inc’s price movement after its last earnings report?
Rapt Therapeutics Inc reported an EPS of -€1.054 in its last earnings report, missing expectations of -€0.295. Following the earnings report the stock price went up 0.99%.
Which hedge fund is a major shareholder of Rapt Therapeutics Inc?
Currently, no hedge funds are holding shares in DE:0RA
---
RAPT Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€5.47 (447.47% Upside)
€5.47 (447.47% Upside)
Blogger Sentiment
Bullish
DE:0RA Sentiment 70%
Sector Average 69%
Sector Average 69%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.76%
12-Months-Change
Fundamentals
Return on Equity
-77.09%
Trailing 12-Months
Asset Growth
38.65%
Trailing 12-Months
Company Description
Rapt Therapeutics Inc
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
---
0RA Stock 12 Month Forecast
Average Price Target
€5.47
▲(447.47% Upside)
Technical Analysis
BioCryst
―
Fate Therapeutics
―
Cara Therapeutics
―
Tonix Pharma
―
Arvinas Holding Company
―
Best Analysts Covering 0RA
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-24.81%
downgraded a sell rating 5 months ago
Copying Anupam Rama's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -24.81% per trade.
---